Prostatic Neoplasms: all 6,484 studies
Page 47 of 65. Open to participants first (1,415), then studies with results posted, then the rest; newest registration first within each.
- Registry to Measure the Impact of Adding Genomic TestingTerminatedNCT02454595
- Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone MetastasesActive, not recruitingNCT02454543Not applicable
- Exercise, Prostate Cancer and Circulating Tumour CellsCompletedNCT02453139Not applicable
- Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate CancerCompletedNCT02453009Phase 2
- Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT02452008Phase 2
- Decision Support Tools for Men With Prostate Cancer- Clinical & Lifestyle ModelCompletedNCT02451345Not applicable
- Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in GermanyCompletedNCT02450812
- The Detection of Circulating Tumor Cells (CTCs) in Patients With Prostatic Cancer Undergoing Cryosurgery Combined With DC-CIK TreatmentCompletedNCT02450435
- Study Comparing MRI/Ultrasound Fusion-guided Prostate Biopsy Versus Systematic Transrectal Ultrasound-guided BiopsyStatus unknownNCT02450266Not applicable
- MRI With C13 Pilot Study Prostate CancerTerminatedNCT02450201Early Phase 1
- Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate CancerActive, not recruitingNCT02446444Phase 3
- Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate CancerActive, not recruitingNCT02446405Phase 3
- Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by SurgeryStatus unknownNCT02446366Not applicable
- Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.CompletedNCT02445976Phase 2
- Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate CancerCompletedNCT02441894Phase 4
- Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate CancerStatus unknownNCT02440802
- A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPCTerminatedNCT02438007Phase 3
- Impact of Preoperative HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Prostate CancerStatus unknownNCT02436122
- Active Surveillance Exercise Clinical TrialCompletedNCT02435472Not applicable
- Assessment of 3D Transperineal Ultrasound Imaging w/ Matrix Array Transducers in Prostate RadiotherapyTerminatedNCT02432820
- Radiologically Guided Biopsies of mCRPCCompletedNCT02432001
- Effectiveness of Community-based Football in Prostate CancerCompletedNCT02430792Not applicable
- Irreversible Electroporation(IRE) For Unresectable Prostatic NeoplasmsWithdrawnNCT02430649Not applicable
- NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate CancerTerminatedNCT02429804Phase 1
- Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSACompletedNCT02429193Phase 2
- Optimizing Abiraterone TherapyCompletedNCT02426333
- Molecular Effects of a Multi-carotenoids (MCS) New Agent on Prostate Cancer ChemopreventionStatus unknownNCT02426216
- Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)CompletedNCT02425592
- Prospective Assessment of Image Registration for the Diagnosis of Prostate CancerCompletedNCT02425228
- Shear Wave Elastography of Prostate CancerCompletedNCT02425163Phase 2
- A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate CancerWithdrawnNCT02424513Phase 2
- Study to Determine the Feasibility, Evaluability and Variability in Markers of Drug Action in Castration Resistant Prostate CancerCompletedNCT02424448
- Phase I Clinical Trial of Cryoimmunotherapy Against Prostate CancerCompletedNCT02423928Phase 1
- Stereotactic Volumetric Radiotherapy in Prostate CancerCompletedNCT02423889Phase 2
- Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active SurveillanceTerminatedNCT02421575Early Phase 1
- Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate CancerCompletedNCT02420977Early Phase 1
- AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)WithdrawnNCT02420587Phase 2
- Informed Decision Making Intervention in Screening for Prostate Cancer of Predominantly African American Participants in a Community Outreach ProgramTerminatedNCT02419846Not applicable
- Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate CancerCompletedNCT02415621Early Phase 1
- Relationship of Mitochondrial Enzymes With Cancer Related FatigueCompletedNCT02414971
- A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSFCompletedNCT02411786Phase 1
- Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate CancerCompletedNCT02410044
- Exercise Training as a Novel Primary Therapy for Men With Localised Prostate CancerCompletedNCT02409212Phase 2
- Use of Non-invasive 4D Ultrasound Clarity System in Prostate IMRT/RapidArc TherapyStatus unknownNCT02408497
- A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade TherapyCompletedNCT02405858Phase 4
- Utilizing MRI to Study the Effect of Sulforaphane on Prostate CancerTerminatedNCT02404428Not applicable
- Comparison Between Conventional and Model-based Infusion Strategy of IV PCA in Patients Undergoing RALPCompletedNCT02402621Not applicable
- Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone MetastasesCompletedNCT02398526
- Using Serum Parathyroid Hormones and Calcium to Improve Prostate Cancer DiagnosisCompletedNCT02397629
- Stereotactic Prostate Adaptive Radiotherapy Utilising Kilovoltage Intrafraction MonitoringCompletedNCT02397317Not applicable
- A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate CancerWithdrawnNCT02396368Phase 1
- Gallium-68 Citrate PET Used in Prostate CancerCompletedNCT02391025Early Phase 1
- Vaccination in Prostate Cancer (VANCE)CompletedNCT02390063Phase 1
- Evaluation of Clarity Ultrasound Guidance for Prostate TherapyCompletedNCT02388308
- Prostate Magnetic Resonance Imaging in Patient With Previous Negative BiopsiesCompletedNCT02388126Not applicable
- Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation TherapyCompletedNCT02382094Phase 3
- G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate CancerCompletedNCT02381236Phase 2
- Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)CompletedNCT02380274
- PRostate Evaluation for Clinically Important Disease: Sampling Using Image-guidance Or Not?CompletedNCT02380027Phase 3
- Exercise Intervention Metabolic Syndrome Prostate Cancer Black MenCompletedNCT02379559Not applicable
- Development of a Therapeutic Education Program for Patients Operated for Prostate CancerCompletedNCT02379260Not applicable
- A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPCTerminatedNCT02378870Phase 2
- Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer PatientsCompletedNCT02376296
- Developing a Safer and More Accurate Device for Biopsies of Suspected Prostate CancerStatus unknownNCT02375035
- Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate CancerTerminatedNCT02370355
- Micro RNAs to Predict Response to Androgen Deprivation TherapyCompletedNCT02366494
- Transrectal Photoacoustic Imaging of the ProstateTerminatedNCT02365883
- A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology SettingCompletedNCT02364531
- Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) SubjectsCompletedNCT02363855Phase 1
- PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.Status unknownNCT02362620
- A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate CancerCompletedNCT02361086Phase 1/2
- Focal Laser Ablation of Prostate TissueCompletedNCT02357121Early Phase 1
- Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access StudyApproved for marketingNCT02355054
- Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate CancerActive, not recruitingNCT02353819Phase 1
- Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise TestingCompletedNCT02353715
- Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate CancerTerminatedNCT02349139Phase 1
- Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-ProstatectomyCompletedNCT02349022Phase 2
- Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.CompletedNCT02346578Phase 2
- High-Dose Brachytherapy in Treating Patients With Prostate CancerCompletedNCT02346253Not applicable
- Feasibility Study of Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer: Cyberknife vs. VMATStatus unknownNCT02344667Phase 2
- Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate CancerCompletedNCT02344017Phase 1/2
- Single Fraction Real-time High-Dose-Rate Brachytherapy in Patients With Low and Intermediate Risk Prostate CancerStatus unknownNCT02342054Phase 2
- SmartTarget: BIOPSYCompletedNCT02341677Not applicable
- A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate CancerCompletedNCT02341404Phase 2
- Phase II Trial of SBRT + or - IMRT in Treatment of Patients With Clinically Confined Prostate AdenocarcinomaCompletedNCT02339948Not applicable
- Stereotactic Body Radiotherapy vs Intensity-modulated Radiotherapy in Prostate CancerActive, not recruitingNCT02339701Not applicable
- Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate CancerCompletedNCT02339168Phase 1
- Safety and Efficacy Study of Mix Vaccine in Prostate Carcinoma PatientCompletedNCT02338700Phase 1/2
- Stereotactic Body Radiotherapy for Stage I-III Prostate CancerStatus unknownNCT02334579Not applicable
- Effects of EPA on Prostate Cancer Cells Proliferation and Quality of LifeActive, not recruitingNCT02333435Phase 2
- MRI in Active Surveillance of Prostate CancerCompletedNCT02326246Not applicable
- Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before ProstatectomyCompletedNCT02324998Phase 1
- C-arm Cone-beam CT in Prostate BrachytherapyStatus unknownNCT02322931Not applicable
- Prostate Cancer Stereotactic RadiotherapyCompletedNCT02319239Not applicable
- MR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer ResearchCompletedNCT02313623
- Stereotactic Body Radiotherapy for Organ Confined Prostate CancerStatus unknownNCT02313298Phase 2
- Evaluation of Treatment Response Using Multiparametric MRI After Prostate RadiotherapyActive, not recruitingNCT02312401Phase 2
- Carboplatin in Castration-resistant Prostate CancerTerminatedNCT02311764Phase 2
- Hypofractionated Radiotherapy for Prostate CancerCompletedNCT02311049Phase 2
- Randomized MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated RadiotherapyActive, not recruitingNCT02307058Not applicable